<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>G. Mamprin | </title>
    <link>https://solon-karapanagiotis.com/author/g.-mamprin/</link>
      <atom:link href="https://solon-karapanagiotis.com/author/g.-mamprin/index.xml" rel="self" type="application/rss+xml" />
    <description>G. Mamprin</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><copyright>Â© Solon Karapanagiotis 2018-2021</copyright><lastBuildDate>Sat, 01 Jun 2013 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://solon-karapanagiotis.com/media/icon.png</url>
      <title>G. Mamprin</title>
      <link>https://solon-karapanagiotis.com/author/g.-mamprin/</link>
    </image>
    
    <item>
      <title>Adherence to the administration of aerosolized promixin with the I-neb adaptive aerosol delivery (AAD) system, lung function and administration times in patients with cystic fibrosis (CF)</title>
      <link>https://solon-karapanagiotis.com/publication/adherence/</link>
      <pubDate>Sat, 01 Jun 2013 00:00:00 +0000</pubDate>
      <guid>https://solon-karapanagiotis.com/publication/adherence/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
